| Unadjusted b | Adjusted c | |||
---|---|---|---|---|---|
 | Na | Median (IQR) Months | P | HR (95% CI) | P |
Walking unsupported | |||||
 HUU-reference | 69 | 13 (11, 14) |  |  |  |
 HIV+, 6-mo VL <1000 c/mL | 28 | 15 (13, 16) | 0.0009 | 0.58 (0.36, 0.92) | 0.02* |
 HIV+, 6-mo VL ≥1000 c/mL | 25 | 16 (13, 20) | 0.0001 | 0.43 (0.24, 0.76) | 0.004 |
 HIV+, 6-mo CD4% ≥25% | 27 | 14 (13, 15) | 0.02 | 0.73 (0.46, 1.16) | 0.2* |
 HIV+, 6-mo CD4% <25% | 27 | 17 (13, 20) | <0.0001 | 0.35 (0.19, 0.61) | <0.001 |
 HIV+, 6-mo WAZ ≥ −2 | 38 | 15 (13, 16) | 0.001 | 0.59 (0.39, 0.90) | 0.014* |
 HIV+, 6-mo WAZ < −2 | 15 | 17 (13, 22) | <0.0001 | 0.26 (0.13, 0.53) | <0.001 |
Monosyllabic speech | |||||
 HUU-reference | 72 | 12 (10, 13) |  | - | - |
 HIV+, 6-mo VL <1000 c/mL | 28 | 15 (12, 16) | <0.0001 | 0.28 (0.16, 0.46) | <0.001* |
 HIV+, 6-mo VL ≥1000 c/mL | 24 | 15 (14, 19) | <0.0001 | 0.20 (0.11, 0.36) | <0.001 |
 HIV+, 6-mo CD4% ≥25% | 27 | 14 (12, 16) | <0.0001 | 0.33 (0.21, 0.55) | <0.001* |
 HIV+, 6-mo CD4% <25% | 26 | 16 (14, 19) | <0.0001 | 0.14 (0.08, 0.27) | <0.001 |
 HIV+, 6-mo WAZ ≥ −2 | 37 | 14 (13, 16) | <0.0001 | 0.26 (0.16, 0.42) | <0.001* |
 HIV+, 6-mo WAZ < −2 | 15 | 16 (15, 19) | <0.0001 | 0.15 (0.07, 0.29) | <0.001 |